This is an Open Access article licensed under the terms of the Creative Commons AttributionNonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only. PKCε. The present study aimed at understanding the mechanism of DCP-LA-induced PKCε activation. Methods: Point mutation in the C2-like domain on PKCε was carried out, and each kinase activity was monitored in PC-12 cells using a föerster resonance energy transfer (FRET) probe with cyan fluorescent protein (CFP) and yellow fluorescent protein (YFP) at the N-and C-terminal ends of PKCε, respectively, or in the cell-free systems using a reversed phase highperformance liquid chromatography (HPLC). Intracellular PKCε mobilization was monitored in PC-12 cells using mRuby-conjugated PKCε. DCP-LA binding to PKCε was assayed using a fluorescein conjugated to DCP-LA at the carboxyl-terminal end (Fluo-DCP). Uptake of DCP-LA into cells was measured in PC-12 ells. Results: In the FRET analysis, DCP-LA decreased the ratio of YFP signal intensity/CFP signal intensity in PC-12 cells and in the cell-free kinase assay, DCP-LA increased area of phosphorylated PKC substrate peptide, indicating DCP-LAinduced PKCε activation. These effects were significantly suppressed by replacing Arg50 and Ile89 by Ala or Asn in the C2-like domain of PKCε. In the fluorescent cytochemistry, DCP-LA did not affect intracellular PKCε distribution. In the cell-free binding assay, Fluo-DCP, that had no effect on the potential for PKCε activation, bound to PKCε, and the binding was inhibited only by mutating Ile89. Extracellularly applied DCP-LA was taken up into cells in a concentrationdependent manner. Although no activation was obtained in the cell-free kinase assay, the broad PKC activator PMA activated PKCε in PC-12 cells in association with translocation towards the cell surface, which was inhibited by mutating I89A. Conclusion: Unlike PMA DCP-LA activates cytosolic PKCε by binding to the phosphatidylserine binding/associating sites Arg50 and Ile89, possibly at the carboxyl-terminal end and the cyclopropane rings, respectively.
DCP-LA Activates Cytosolic PKCε by

Introduction
Accumulating evidence has shown that the linoleic acid (LA) derivative 8-[2-(2-pentylcyclopropylmethyl)-cyclopropyl]octanoic acid (DCP-LA) could improve dementia including Alzheimer's disease [1] [2] [3] [4] [5] [6] [7] [8] . The effect is mainly attributed to selective and direct activation of PKCε involving delivery of α7 ACh receptor to the presynaptic membrane surface and release of neurotransmitters [9] [10] [11] [12] . In our earlier study, DCP-LA-induced PKCε activation was inhibited by adding phosphatidylserine (PS) [13] . This raises the possibility that DCP-LA activates PKCε by interacting with the PS binding site on PKCε. The accurate binding sites, however, have not been identified.
The present study was conducted to answer this issue. We show here that unlike the broad PKC activator phorbol 12-myristate 13-acetate (PMA) DCP-LA binds to Arg50 and Ile89 in the C2-like domain of PKCε and activates PKCε localized in the cytosol, but not at the plasma membrane. We also show that LA activates PKCε by binding to the same sites as DCP-LA.
Materials and Methods
DNA subcloning and site-directed mutagenesis
The plasmid containing the normal rat PKCε was constructed. For the PKCε mutants the amino acid residues in the C2-like domain of PKCε were replaced by Ala or Asn.
FRET analysis
The vector for FRET probe with CFP and YFP at the N-and C-terminal ends of PKCε, respectively, was constructed and transfected into PC-12 cells using a Lipofectamine LTX-PLUS (Invitrogen, Carlsbad, CA, USA). Forty-eight hours later FRET monitoring was carried out with Zeiss LSM510 META inverted microscope (Oberkochen, Germany) by the method as described previously [14] . The CFP and YFT fluorescent signals were detected at an absorbance of 474 and 506 nm, respectively, using an excitation light of 458 nm. The FRET ratio (YFP signal intensity/CFP signal intensity) was calculated using an ImageJ software (National Institutes of Health, USA).
Fluorescent cytochemistry
PKCε, conjugated with the red fluorescent protein eqFP611, mRuby, was expressed into PC-12 cells, and intracellular PKCε mobilization was monitored with a confocal scanning laser microscope (Axiovert/ LSM510; Carl Zeiss, Oberkochen, Germany).
Cell-free PKCε assay
In the cell-free systems, PKCε activity was assayed by the method previously described [13, 15] . Briefly, a synthetic PKC substrate peptide (10 μM) was reacted with wild-type and mutant PKCε in a Ca
2+
-and PSfree solution containing DCP-LA, lipids or PMA at 30°C for 5 min. After loading on a reversed phase HPLC (LC-10ATvp, Shimadzu Co., Kyoto, Japan), a substrate peptide peak and a new product peak were detected at an absorbance of 214 nm. Areas for non-phosphorylated and phosphorylated PKC substrate peptide were measured, and phosphorylated substrate peptide (pmol/min) was used as an index of PKC activity. PKCε activities induced by DCP-LA, lipids and PMA were calculated by subtracting the basal PKCε activities in the presence of DMSO (Δpmol/min).
PKCε binding assay
Fluo-DCP was constructed by the method previously described [16] . Briefly, wild-type and mutant PKCε were reacted with Fluo-DCP in the presence and absence of non-conjugated DCP-LA, and then, separated by blue native-polyacrylamide gel electrophoresis. The fluorescent signals were visualized using a FluoroPhoreStar3000 (Anatech, Tokyo, Japan). 
Assay of intracellular distribution of DCP-LA
After treatment with DCP-LA for 5 min, lysates from PC-12 cells were separated into the cytosolic and plasma membrane components. DCP-LA in each component was labeled with 9-anthryldiazomethane (ADAM)(Funakoshi, Tokyo, Japan) and then, the sample solution was loaded onto the HPLC system. ADAM was detected at an excitation wavelength of 365 nm and an emission wavelength of 412 nm using a fluorescence detector.
Statistical analysis
Statistical analysis was carried out using analysis of variance (ANOVA) followed by a Bonferroni correction.
Results
DCP-LA activates PKCε without translocation towards the cell surface
We initially monitored PKCε activity in PC-12 cells using a FRET probe, which has CFP and YFP at the N-and C-terminal ends of PKCε, respectively (Fig. 1A) . A conformational change of PKCε from the inactive form to the active form leads to an enhancement of the CFP signal intensity from the YFP signal intensity (Fig. 1A) , and therefore, a decrease and an increase in the ratio (YFP signal intensity/CFP signal intensity) correspond to activation and inactivation of PKCε, respectively (Fig. 1B) . PMA, DCP-LA and LA significantly decreased the FRET ratio as compared with that for DMSO (Fig. 1C) . This implies that PMA, DCP-LA and LA activate PKCε in PC-12 cells.
PKCε contains the PS binding/associating sites in the C2-like domain (Fig. 1D ) [17] . PMA-induced PKCε activation was significantly inhibited by replacing Trp23 (W23A), Arg50 (R50A) and Ile89 by Ala (I89A) (Fig. 1E) . Similarly, activation of mutant PKCεW23A (mPKCεW23A), -R50A and -I89A induced by DCP-LA was significantly attenuated as compared with that for wild-type PKCε (wPKCε) (Fig. 1E) . These results suggest that PMA and DCP-LA activate PKCε by interacting with the PS binding/associating sites Trp23, Arg50 and Ile89 in the C2-like domain.
In the fluorescent cytochemistry in PC-12 cells expressing mRuby-conjugated PKCε, PMA translocated wPKCε to the cell surface, but otherwise such effect was not found with DCP-LA and LA (Fig. 1F ). This suggests that PKCε activation does not parallel with PKCε translocation towards the cell surface. PMA did not affect intracellular mPKCεI89A distribution, while mPKCεW23A, -R50A and -Y91A were translocated towards the cell surface in a fashion similar to that for wPKCε (Fig. 1F) .
DCP-LA activates PKCε by interacting with Arg50 and Ile89 in the C2-like domain
In the cell-free PKCε assay, DCP-LA-induced activation of mPKCεR50A, -I89A and -I89N (replacement of Ile89 by Asn) significantly reduced as compared with that for wPKCε, but no significant reduction was found with mPKCεW23A and other mPKCε with replacement of Arg26 (R26A), Arg32 (R32A), His85 (H85A), Asp86 (D86A), Pro88 (P88A), Gly90 (G90A), Tyr91 (Y91A), Asp92 (D92A) and Asp93 (D93A) by Ala ( Fig. 2A) .
Likewise, LA activated wPKCε to an extent similar to that for DCP-LA, and the activation was significantly reduced by mutating Arg50 and Ile89 (Fig. 2B) . Another unsaturated free fatty acid oleic acid (OA) and the saturated free fatty acid stearic acid (SA) activated wPKCε, but to a lesser extent than that for DCP-LA or LA, and the activation was also reduced by mutating Arg50 and Ile89 (Fig. 2C, D) . Surprisingly, no activation of wPKCε was obtained with PMA (Fig. 2E) . This, in the light of the fact that cell-free PKCε assay was carried out in a PS-free solution, suggests that PS is required for PMA-induced PKCε activation. Dioleoyl-PS (DO-PS) still activated wPKCε, and the activation was significantly reduced by mutating Ile89 and Gly90, but not Arg50 (Fig. 2F) . This suggests that PS binds to Ile89 and Gly90, thereby partially activating PKCε.
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DCP-LA directly binds to free PKCε
To obtain evidence for DCP-LA binding to PKCε, we constructed Fluo-DCP (Fig. 3A) . Fluo-DCP produced a single fluorescent signal band at 87 kDa in the electrophoresed gel, corresponding to the molecule of PKCε, and the signal was attenuated or abolished by cotreatment or pretreatment with non-conjugated DCP-LA (Fig. 3A) . The signal intensity for Fluo-DCP binding to mPKCεI89A and -I89N was significantly lower than that to wPKCε, and no significant effect was obtained with the other mutants including mPKCεR50A (Fig. 3B ). In the cell-free kinase assay, Fluo-DCP activated wPKCε to an extent similar to that for DCP-LA (Fig. 3C) . These results indicate that DCP-LA directly binds to Ile89 in the PS binding site, to 
DCP-LA is taken up into cells
We finally examined whether extracellularly applied DCP-LA is taken up into cells. When extracellularly applied to PC-12 cells, cytosolic DCP-LA increased in a concentration (10 nM-1 μM)-dependent manner in parallel with increased concentrations in the plasma membrane (Fig. 4) . This suggests that DCP-LA is capable of activating PKCε localized in the cytosol.
Discussion
PMA is shown to activate PKCε by binding to the C1 domain [18] . In the present study, PMA activated wPKCε in PC-12 cells, and the activation was inhibited by replacing Trp23, Fig. 4 . Uptake of DCP-LA into cells. PC-12 cells were treated with DCP-LA at concentrations as indicated, and DCP-LA in the cytosolic and plasma membrane components was quantified with the HPLC systems. Data represent the mean (± SEM) DCP-LA concentration (pmol/μg protein)(n=4 independent experiments). 
